Zerion Pharma has entered into a strategic partnership with Hovione to accelerate the commercialization of the Dispersome technology.
Through their partnership, the two companies are offering pharma and biotech companies worldwide access to an innovative drug delivery platform combined with an unparalleled experience in formulation development, scale up and GMP manufacturing, they state. This combination provides customers in the pharma industry with a line of sight over the entire drug development life cycle from the preclinical phase to commercial drug product.
Financial terms are not disclosed
Under the terms of the agreement, the companies will market the Dispersome technology both jointly and individually to the pharmaceutical industry. In addition to the co-marketing of the Dispersome technology, both parties have agreed to further develop the technology that is already protected by several patent families until 2042. Financial terms of the agreement are not disclosed.
“We consider Hovione the global leader in the field of producing amorphous solid dispersions by spray-drying. More importantly for us, this leadership has resulted in Hovione being the main producer of novel FDA-approved drugs formulated as amorphous solid dispersions. Over the last 5 years, Hovione has been responsible for the commercial manufacture of most of the amorphous solid dispersions approved by the FDA. Incorporating these competencies in our offering to the pharma industry both validates the strength of our Dispersome platform and provides us and our pharma partners immediate access to the highest quality in upscaling and commercial GMP manufacturing. While we already have six ongoing industry partnerships, we expect this number to increase significantly during the coming years due to our collaboration,” says Ole Wiborg, CEO of Zerion.